Page 71«..1020..69707172

22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and…

By Dr. Matthew Watson

The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation

See more here:
22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and...

To Read More: 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and…
categoriaGlobal News Feed commentoComments Off on 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and… | dataOctober 19th, 2020
Read All

Rafarma Closes Biocogency Merger

By Dr. Matthew Watson

Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (http://www.slavich.ru), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma (http://kraspharma.ru) and Bebig (http://en.bebig.ru/) being added in due course.

Read more from the original source:
Rafarma Closes Biocogency Merger

To Read More: Rafarma Closes Biocogency Merger
categoriaGlobal News Feed commentoComments Off on Rafarma Closes Biocogency Merger | dataOctober 19th, 2020
Read All

Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

By Dr. Matthew Watson

DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of Nephrology (ASN) Kidney Week 2020, which is being held virtually from October 22-25, 2020. The abstracts will highlight clinical and nonclinical data from novel drug formulations being developed for the treatment of chronic kidney disease (CKD), acute kidney injury (AKI), and COVID-19.

Read the original post:
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

To Read More: Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020
categoriaGlobal News Feed commentoComments Off on Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020 | dataOctober 19th, 2020
Read All

Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR…

By Dr. Matthew Watson

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

See the article here:
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR...

To Read More: Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR…
categoriaGlobal News Feed commentoComments Off on Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR… | dataOctober 19th, 2020
Read All

Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

By Dr. Matthew Watson

MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial Results on Monday, November 2, 2020, at 4:30pm Eastern Time.

More here:
Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

To Read More: Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call
categoriaGlobal News Feed commentoComments Off on Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call | dataOctober 19th, 2020
Read All

Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

By Dr. Matthew Watson

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769.

Link:
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

To Read More: Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
categoriaGlobal News Feed commentoComments Off on Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results | dataOctober 19th, 2020
Read All

Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci

By Dr. Matthew Watson

Daix (France), October 19, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to odiparcil, the Company’s clinical-stage drug candidate for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.

See more here:
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci

To Read More: Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci
categoriaGlobal News Feed commentoComments Off on Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci | dataOctober 19th, 2020
Read All

Orion upgrades full-year outlook for 2020

By Dr. Matthew Watson

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 19 OCTOBER 2020 at 20.35 EEST

The rest is here:
Orion upgrades full-year outlook for 2020

To Read More: Orion upgrades full-year outlook for 2020
categoriaGlobal News Feed commentoComments Off on Orion upgrades full-year outlook for 2020 | dataOctober 19th, 2020
Read All

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

By Dr. Matthew Watson

ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2

Originally posted here:
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

To Read More: ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program
categoriaGlobal News Feed commentoComments Off on ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | dataOctober 19th, 2020
Read All

Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

By Dr. Matthew Watson

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release third quarter 2020 financial and operating results after market close on Monday, November 2, 2020. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

Read the rest here:
Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

To Read More: Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call
categoriaGlobal News Feed commentoComments Off on Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call | dataOctober 19th, 2020
Read All

Replimune Appoints Tanya Lewis to the Board of Directors

By Dr. Matthew Watson

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.

Read the original post:
Replimune Appoints Tanya Lewis to the Board of Directors

To Read More: Replimune Appoints Tanya Lewis to the Board of Directors
categoriaGlobal News Feed commentoComments Off on Replimune Appoints Tanya Lewis to the Board of Directors | dataOctober 19th, 2020
Read All

Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

By Dr. Matthew Watson

EMERYVILLE, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be report financial results for the third quarter 2020 after market close on Thursday, November 12, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

See more here:
Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

To Read More: Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020
categoriaGlobal News Feed commentoComments Off on Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020 | dataOctober 19th, 2020
Read All

UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

By Dr. Matthew Watson

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

View post:
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

To Read More: UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 | dataOctober 19th, 2020
Read All

Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

By Dr. Matthew Watson

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

Continued here:
Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

To Read More: Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member
categoriaGlobal News Feed commentoComments Off on Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member | dataOctober 19th, 2020
Read All

Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

By Dr. Matthew Watson

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

Originally posted here:
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

To Read More: Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 | dataOctober 19th, 2020
Read All

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

By Dr. Matthew Watson

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Go here to see the original:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

To Read More: First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
categoriaGlobal News Feed commentoComments Off on First Patient Dosed in Phase II Trial to Treat Complications in COVID-19 | dataOctober 17th, 2020
Read All

Theratechnologies Appoints Two New Board Members

By Dr. Matthew Watson

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.

Continued here:
Theratechnologies Appoints Two New Board Members

To Read More: Theratechnologies Appoints Two New Board Members
categoriaGlobal News Feed commentoComments Off on Theratechnologies Appoints Two New Board Members | dataOctober 17th, 2020
Read All

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

By Dr. Matthew Watson

Originally posted here:
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

To Read More: Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
categoriaGlobal News Feed commentoComments Off on Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol | dataOctober 17th, 2020
Read All

Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

By Dr. Matthew Watson

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share.  The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

Link:
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

To Read More: Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock
categoriaGlobal News Feed commentoComments Off on Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock | dataOctober 17th, 2020
Read All

Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

By Dr. Matthew Watson

MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.

See the original post here:
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

To Read More: Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
categoriaGlobal News Feed commentoComments Off on Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen | dataOctober 17th, 2020
Read All

Page 71«..1020..69707172